Using electronic monitoring (EM), Marin et al prospectively demonstrated that poor adherence to the tyrosine kinase inhibitor (TKI), imatinib, in CML, adversely impacts molecular and cytogenetic response 5,6.This landmark study provided proof of concept that non-adherence to oral anti-cancer in hematological malignancies may be associated with poor responses and decreased survival. Our study group is currently analyzing data from our prospective interventional study aimed at improving adherence to TKIs in CML (NCT01768689).